Eastover Investment Advisors LLC Purchases 1,166 Shares of Johnson & Johnson (NYSE:JNJ)

Eastover Investment Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 3.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 38,382 shares of the company’s stock after buying an additional 1,166 shares during the period. Johnson & Johnson accounts for approximately 3.2% of Eastover Investment Advisors LLC’s holdings, making the stock its 16th biggest position. Eastover Investment Advisors LLC’s holdings in Johnson & Johnson were worth $6,016,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson during the third quarter valued at $27,000. FNY Investment Advisers LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at about $37,000. Tower View Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC lifted its position in shares of Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $48,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.1 %

NYSE:JNJ opened at $158.19 on Monday. The company has a market cap of $381.20 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 2.66 and a beta of 0.53. The stock has a fifty day simple moving average of $158.58 and a 200-day simple moving average of $156.63. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same quarter last year, the firm posted $2.35 earnings per share. The business’s revenue for the quarter was down 9.7% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. The ex-dividend date was Friday, February 16th. Johnson & Johnson’s payout ratio is 34.47%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on JNJ shares. Morgan Stanley decreased their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Raymond James boosted their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 28th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Read Our Latest Report on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.